Halothane


Concise Prescribing Info
Indications/Uses
Induction and maintenance of general anaesth.
Dosage/Direction for Use
Adult : Inhalation Induction: 0.5% v/v in oxygen or mixture of nitrous oxide and oxygen, may increase gradually up to 2-4% v/v. Maintenance: 0.5-2% v/v depending on the flow rate used.
Dosage Details
Inhalation/Respiratory
Induction and maintenance of general anaesthesia
Adult: Induction: 0.5% v/v of halothane in oxygen or mixture of nitrous oxide and oxygen, increase gradually according to response to a concentration of 2-4% v/v. Maintenance: 0.5-2% v/v depending on the flow rate used.
Child: Induction: 1.5-2% v/v. Maintenance: 0.5-1.5% v/v.
Incompatibility
Reacts w/ many metals. Rubber and some plastics deteriorate when in contact w/ halothane vapour or liq.
Contraindications
Known or suspected susceptibility to malignant hyperthermia, raised CSF pressure, history of unexplained jaundice or acute hepatic damage from previous exposure to halothane. Childn <18 yr undergoing outpatient dental surgery.
Special Precautions
Patient w/ phaeochromocytoma, myasthenia gravis, renal failure, pre-existing hepatic disease. Childn. Pregnancy and lactation.
Adverse Reactions
Post-op nausea, vomiting, and shivering; resp depression, hypotension, skeletal muscle relaxation, bradycardia.
Potentially Fatal: Hepatotoxicity, malignant hyperthermia, cardiac arrhythmias.
Patient Counseling Information
May impair ability to drive or operate machinery.
MonitoringParameters
Monitor pulse and BP.
Drug Interactions
Increased risk of ventricular dysrhythmias w/ epinephrine. Increased risk of malignant hyperthermia w/ suxamethonium. Prolonged recovery from anaesth w/ concurrent use of ketamine for induction. May potentiate response to non-depolarising muscle relaxants, hypotensive agents (e.g. hexamethonium bromide, trimetaphan camsilate).
Action
Description: Halothane is a potent non-flammable inhalational anaesth which depresses both cerebral function and sympathetic activity. It suppresses salivary, bronchial and gastric secretions and dilates the bronchioles.
Pharmacokinetics:
Absorption: Absorbed on inhalation.
Distribution: Soluble in the neutral fats of adipose tissue. Crosses the placenta and enters breast milk.
Metabolism: Metabolised hepatically to form trifluoroacetic acid, bromide and Cl salts via oxidative pathway, and fluoride salts via reductive pathway.
Excretion: Via lungs (up to 80% as unchanged drug).
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 25°C.
ATC Classification
N01AB01 - halothane ; Belongs to the class of halogenated hydrocarbons. Used as general anesthetics.
Disclaimer: This information is independently developed by MIMS based on Halothane from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in